Navigating Outpatient Bispecific Antibody Administration in Lymphoma: Practical Solutions for Community Oncology Practices

Program Description

Bispecific antibodies (BsAbs) have expanded the treatment landscape for patients with relapsed/refractory lymphomas. Yet, as these agents gain broader approvals and their use shifts increasingly to community settings, oncology teams face significant challenges in ensuring safe, standardized, and accessible care. This multidisciplinary panel discussion explores clinical and operational issues associated with the use of BsAbs, including institutional readiness and infrastructure, which encompasses facility needs, formulary decisions, and REMS compliance. Panelists will also detail evidence-based prophylactic strategies to address toxicity management and escalation of care, such as defined protocols for safe step-up dosing and the logistics of emergency interventions. Finally, the panel will address site-of-care coordination and financial impact, providing best practices for successfully transitioning patients from academic to community settings, navigating complex insurance approvals and financial barriers, and developing practical solutions to minimize travel burden for rural patients. These specialized skills in operationalizing complex care pathways, leading safety and monitoring initiatives, and streamlining financial and communication workflows will support oncology pharmacists as they become leaders in making BsAb therapy safe and accessible for patients with lymphomas in their communities.

Target Audience: Oncology Pharmacist

Type of Activity: Application
Release date: December 19, 2025
Expiration date: December 19, 2026
Learner level: Foundational, Intermediate, Advanced
Time to complete activity: 1.5 hour
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Determine resource and infrastructure needs for outpatient bispecific antibody (BsAb) administration in community oncology, including staffing, infusion capacity, and supportive care
• Examine strategies for escalating care for patients experiencing CRS and/or ICANS based on severity grading and available institutional resources
• Identify key factors influencing site-of-care decisions for outpatient BsAb administration, including patient needs, institutional capabilities, and payer considerations

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-352-H01-P. The activity is available for CE credit through December 19, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, view the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: Sanofi, BMS, Pfizer

James A. Davis PharmD, BCOP, has the following relevant financial relationships with ineligible companies to disclose:

Consultant: BMS, Janssen, GSK

Speakers Bureau: Janssen

The following contributors have no relevant financial relationships with ineligible companies to disclose:

Faculty

Joseph G. Bennett, MD

Lindsey Hendrickson, FNP-C

Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Daphne Davis, PharmD, BCOP; Victoria Chirdo; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with ineligible companies to disclose.

Any relevant financial relationships listed for these individuals have been mitigated.

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with ineligible companies to disclose.

Educational Disclaimer

CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms